April 28, 2026
Last Updated: April 2026
Section 280E has been the single largest cost line on the cannabis P&L for forty years. It denies any deduction or credit to a business "trafficking" in a Schedule I or II controlled substance, leaving most cannabis operators paying federal tax on something close to gross profit instead of net income. Effective federal rates north of 70 percent — sometimes north of 90 percent — have been the rule, not the exception.
On April 22, 2026, that math changed for one slice of the industry. The DOJ's final order moving FDA-approved marijuana products and state-licensed medical cannabis to Schedule III removes 280E from those activities. On April 23, Treasury and the IRS announced that formal guidance was coming, including a transition rule that — read at face value — applies the rescheduling to the full taxable year that includes the effective date.
The headline writes itself: 280E is over for medical cannabis. The actual tax position is more complicated than that, and getting it wrong on the FY2026 return will cost real money. This is the operator-and-CPA playbook for the next twelve months — what the order does, what the transition rule means, what to do about prior years, and where the audit risk is now sitting.
Section 280E of the Internal Revenue Code denies "any deduction or credit" for amounts paid or incurred in carrying on a trade or business that consists of trafficking in a Schedule I or II controlled substance. Cost of goods sold remains deductible — that's a constitutional floor, not a § 280E exception — but every operating expense below the gross-profit line, from rent to payroll to marketing to professional fees, is non-deductible.
The math gets ugly fast. A dispensary with $10M in revenue, $4M in COGS, $5M in operating expenses, and $1M of GAAP net income looks like this for federal tax purposes: $10M revenue minus $4M COGS equals $6M of taxable income, on which the C-corp pays roughly $1.26M in federal tax (21 percent), against actual book income of $1M. Effective federal rate: 126 percent. Add state tax in any state that conforms to § 280E, and the picture gets worse.
That has been the cannabis-industry baseline since 1982, and it has shaped every operating, structuring, and financing decision in the industry. Operators have spent enormous effort moving costs above the COGS line via § 263A inventory allocation, restructuring real estate into separate non-trafficking entities, and litigating the boundary of what counts as "trafficking" in cases like CHAMP, Patients Mutual (Harborside), and Olive. The Tax Court has been hostile to creative structuring. The Ninth Circuit has affirmed that hostility consistently.
For a refresher on the finance-controls side of operating under § 280E, our 280E Survival Stack walks through the year-end-close mechanics that any cannabis CFO should already have in place.
Section 280E applies to trafficking in Schedule I or II substances. Schedule III isn't in the statute. The moment an activity moves to Schedule III, § 280E doesn't reach it.
That's the whole basis of the relief. The DOJ's April 22 final order doesn't amend the tax code; it moves part of the cannabis universe out of the schedules § 280E references. The relief is automatic in that sense — there's no taxpayer election, no IRS application, no carve-out to qualify for. If your activity falls within the rescheduled categories, § 280E doesn't apply.
The catch: only certain activities are rescheduled. The order moves to Schedule III only (1) FDA-approved drug products containing marijuana and (2) marijuana subject to a qualifying state-issued license to manufacture, distribute, or dispense for medical purposes only. Everything else stays in Schedule I, including the entire recreational adult-use market. Section 280E continues to apply to recreational cannabis with full force.
Treasury's April 23 announcement makes this explicit: rescheduling generally removes § 280E as a bar to claiming deductions and credits "for businesses that as a result of the Final Order no longer traffic in Schedule I or II controlled substances." Read carefully, the relief is conditioned on the business no longer trafficking in Schedule I or II, not on the business holding a medical license. A licensee that operates in both medical and adult-use lanes is still trafficking in Schedule I as to its adult-use activity, and § 280E still applies to that piece of the business.
That distinction is going to drive the most consequential structuring decisions in the industry for the rest of 2026.
The Treasury/IRS press release of April 23 signaled that the forthcoming guidance will include a transition rule providing that, for purposes of § 280E, the rescheduling generally will be considered to first apply for the business's full taxable year that includes the effective date of the final order — for the business's activities that no longer involve Schedule I or II as a result of the order.
Read straight, that is a generous transition. For a calendar-year filer, FY2026 — the entire year, including pre-April 22 activity — is treated as if the rescheduling applied throughout, for purposes of § 280E, as to the rescheduled activities. The mid-year change at the rescheduling level is smoothed at the tax level.
There are at least four open questions on the transition rule that the formal guidance will need to address:
First, scope of activities. The rule applies to activities that are no longer Schedule I or II as a result of the order. A dispensary running a hybrid medical-and-adult-use operation has to allocate. The guidance will need to spell out the allocation method — direct tracing, gross-receipts pro rata, square-footage, head-of-licensed-product — and operators that pick a method now should be picking one that holds up if the IRS later prescribes a different default.
Second, COGS and § 263A treatment. The cannabis industry spent fifteen years building inventory-cost methodologies optimized for § 280E. With the relief flowing for medical activity, that machinery is partly obsolete and may even be working against you — high COGS allocation that helped under § 280E now just shifts the timing of deductions you can already take. Many operators will find that re-running their § 263A election is the highest-ROI tax move of the year.
Third, NOLs and carryforwards. Operators that have NOL carryforwards generated during 280E-applicable years can use them against post-rescheduling income. The transition rule does not, on its face, restrict that. Whether the IRS attempts to limit pre-effective-date NOLs from offsetting post-rescheduling income is one of the live questions, and operators with sizable NOL carryforwards should be reading the guidance with a microscope.
Fourth, partnership and S-corp passthrough mechanics. Most cannabis operators are not C-corps. The transition rule's treatment of mid-year partner changes, basis adjustments, and § 704(b) allocations is going to be its own technical thicket.
Until the formal guidance issues, a defensible position for the FY2026 return on rescheduled medical activity is to claim deductions and credits on the full year's qualifying activity, document the allocation method, and disclose the position. Aggressive — but with the transition rule signaled in writing by Treasury, defensible. Wait-and-see is also defensible, and is the right call for any operator that doesn't have the cash-tax pressure to act now.
The DOJ's April 23 order encouraged Treasury to consider retroactive § 280E relief for prior tax years. That language is a suggestion, not a mandate, and the IRS has not committed to it.
The retroactive question is the single biggest tax dollar question in the industry. Every medical-side cannabis operator filing under § 280E from 2014 onward could, in theory, file amended returns for open years and claim refunds. The general statute of limitations under § 6511 is three years from the filing date or two years from payment, whichever is later — meaning FY2023, FY2022, and possibly FY2021 returns are still in scope for most filers as of April 2026. Some operators preserved the issue with protective claims; many didn't.
Three positions are emerging in the advisor community:
The aggressive position: file amended returns now for open years claiming § 280E relief on the theory that the substance of medical cannabis activity has been the same all along, and the rescheduling makes legal what was always commercially the same activity. The defense is statutory: § 280E references "Schedule I or II," and Schedule III is the actual current treatment of the activity. The risk is litigation. The IRS is likely to deny these claims and force the question into Tax Court. Operators that take this path should be budgeting for litigation costs and time.
The conservative position: wait for the IRS to issue formal guidance, then file based on what the guidance allows. The cost is opportunity. If the IRS follows the DOJ encouragement and issues retroactive relief, late filers may still be able to claim within the statute of limitations. If the IRS doesn't, the conservative position avoids a fight that probably wasn't winnable anyway.
The middle position: file protective refund claims now to preserve the statute-of-limitations clock for FY2022 and FY2023 returns, then wait on the formal guidance before deciding whether to perfect the claims. This is probably the right move for most operators with material historical 280E payments. Protective claims are inexpensive, well-established, and don't commit the operator to a litigating posture.
Whatever path you pick, document the rationale and the timeline. Retroactivity will be the most-litigated cannabis-tax question of 2026 and 2027, and the audit posture you build now is the audit posture you defend in three years.
The hardest practical problem the rescheduling creates is what to do about the typical multi-state operator running medical and adult-use activity through overlapping legal entities, often in shared facilities, with shared inventory and shared overhead.
Section 280E's "trafficking in a Schedule I or II controlled substance" language is activity-based, not entity-based. An LLC that conducts both medical and adult-use activity is still trafficking in Schedule I as to the adult-use side. The reasonable reading is that § 280E continues to bar deductions allocable to that adult-use activity, and the FY2026 return needs an allocation between the rescheduled and non-rescheduled portions.
That's solvable on paper. In practice, the allocation methodology determines the size of the deduction, and the IRS has a long history of attacking allocation methodologies that produce favorable taxpayer results. Three structuring approaches are getting traction:
Entity segregation. Operators are separating medical activity into a distinct legal entity — sometimes a subsidiary, sometimes a sister LLC under common ownership, sometimes a re-papered organizational chart that was already there. The medical entity holds the medical license, registers with DEA as a Schedule III handler, runs the medical-only inventory, and books the medical-only revenue and expenses. The adult-use entity handles everything else and keeps its § 280E posture. The cleanness of the separation determines the audit defense.
Real-estate segregation. Where the medical and adult-use activity occur in physically distinct space — separate dispensary floors, separate cultivation rooms — operators can run the activity through separate cost centers within the same legal entity, then allocate based on direct tracing rather than pro rata. The Tax Court has been more receptive to direct tracing than to pro rata in 280E cases historically; that should hold.
Functional segregation by SKU or batch. Where the same product is sold into both medical and adult-use channels, operators are tagging at the SKU and batch level and tracing through to the channel. This is data-intensive but defensible if the underlying recordkeeping holds up. It is not realistic for most legacy operators without a serious investment in track-and-trace and ERP integration.
The structuring decision should be driven by the dollar value of the deduction differential, not by what's easiest to implement. For a typical mid-size MSO, the move from a pro rata allocation to a clean entity-segregation structure can mean the difference between $4M and $9M of deductible operating expense in a single year. The cost of the restructuring is dwarfed by the tax benefit.
State tax conformity is its own headache here. We've covered the broader compliance ripple effects in Schedule III, Then What?, and the readiness items in Schedule III, 280E Relief, and the Limits of Rescheduling.
States that conform to the federal Internal Revenue Code don't all conform the same way. Some states adopt the IRC as of a fixed date (static conformity); others adopt it as of the date the state return is filed (rolling conformity). Some states explicitly decoupled from § 280E years ago — California, Massachusetts, New York, Illinois, and Oregon, among others — meaning state-level deductions have been allowed even where federal weren't.
For the FY2026 return, the matrix to think through:
In states that previously decoupled from § 280E, the rescheduling doesn't change the state-side picture much. State deductions were already allowed; the federal deduction now follows.
In conforming states, the rescheduling produces a federal-state matching benefit at the federal effective date. This is the largest cash-flow benefit of the rescheduling for medical operators in those states.
In states with their own cannabis-specific tax regime (excise taxes layered on top of income tax), the rescheduling doesn't touch the excise side. The cost of compliance with state excise taxes — point-of-sale, wholesale, cultivation taxes depending on the state — continues unchanged.
The combined federal-and-state effective rate for a typical medical-side operator is going to drop from somewhere north of 50 percent to somewhere in the 25 to 35 percent range, depending on state. Cannabis Regulators Association estimates the federal effective rate alone for qualifying medical businesses at roughly 20 to 30 percent post-rescheduling. The full picture, after state, looks more like an ordinary high-margin business — for the first time in the industry's history.
Section 280E was the audit issue under Schedule I. Allocation methodology, COGS calculation, and structuring will be the audit issues under Schedule III. The IRS has lost very few § 280E cases in twenty years of enforcement. It is going to fight the allocation methodologies hard.
Three audit risks to flag:
The "single trade or business" issue, revisited. CHAMP recognized that a cannabis dispensary running a separate counseling-services business could allocate expenses between the two. The same analysis is going to apply to the new medical-and-adult-use split, and the IRS is going to argue — probably persuasively in some cases — that a single entity running both activities is a single trade or business with no real allocation basis. Operators relying on allocation within a single entity should be reading CHAMP with fresh eyes.
Inventory and § 263A. Operators that built up generous § 263A inventory allocations to maximize COGS under § 280E now face the question of whether those allocations are defensible going forward. The IRS may argue that inventory costs that were properly capitalizable as COGS are still COGS — but that operating expenses pulled into the inventory through § 263A were optimized for an old regime and need to be re-analyzed.
Substance-over-form challenges to entity restructuring. The IRS has long-standing tools — assignment-of-income doctrine, substance-over-form, sham transaction — to attack restructurings that exist primarily for tax benefit. The cleaner the operational separation between medical and adult-use, the better the restructuring holds up. Sister entities sharing an inventory system and a single bank account aren't going to survive challenge.
For operators that are still figuring out how this affects banking and lending posture, Schedule III and Cannabis Banking and Hemp & Cannabis Payments 2026 cover the practical follow-on.
A defensible FY2026 tax program for a medical-side cannabis operator looks like this:
Re-run your entity chart against the rescheduled activities. Identify the legal entities that hold the qualifying state medical license, identify the activities that fall within the Schedule III scope, and confirm that DEA Schedule III registration applications were filed within the 60-day window that closes June 22.
Pick an allocation methodology and document it in a position paper before the FY2026 return is filed. Direct tracing where possible, pro rata as a fallback, with the rationale spelled out. Update the methodology for the formal IRS guidance once it issues.
Re-evaluate your § 263A election. The cost-allocation approach optimized for § 280E may no longer be the right one. Most operators will find a more conservative § 263A election produces a better total-tax outcome under Schedule III.
File protective refund claims for FY2022 and FY2023 (and FY2021 if the limitations period is still open, which depends on when the original returns were filed). Don't perfect the claims yet; keep them protective until the formal IRS retroactivity position emerges.
Build the FY2026 cash-tax forecast under two scenarios: full transition relief (Treasury's signaled position) and pro rata transition (more conservative IRS interpretation). The cash-flow difference is large enough to drive distribution and capital-allocation decisions.
Update credit-agreement and tax-distribution provisions. Many partnership agreements and credit facilities have tax-distribution mechanics keyed to § 280E. Those need to be redrafted before the FY2026 distribution decisions get made.
Coordinate with state tax. The federal rescheduling doesn't preempt state tax law. The combined-conformity analysis is its own workstream, and it has to happen in parallel with the federal return prep.
Stress-test for the litigation scenario. The April 22 order is going to be challenged. An adverse outcome could undo the rescheduling on a 12- to 24-month timeline. Tax positions taken in FY2026 should anticipate the possibility of having to be unwound.
The DEA hearing scheduled to begin June 29, 2026 will consider whether marijuana as a whole — including recreational — should move to Schedule III. If it does, and if the resulting rule survives challenge, § 280E falls away from the entire industry. The recreational market — which today carries the same 70-to-90 percent effective federal rates the medical market did — moves into ordinary-business tax treatment.
The dollar value of that outcome, across the entire industry, is in the high single-digit billions of dollars per year. Operators are not going to make adult-use investment decisions until they see how the hearing resolves, and that bottlenecks a lot of capital.
If you advise recreational operators: the right posture for FY2026 is to file as you have been, on a § 280E basis, with the recognition that an FY2027 amendment may be appropriate if broader rescheduling proceeds. Don't take the relief now on the recreational side. The IRS won't honor it, and the litigation cost isn't worth the optionality.
The April 22 rescheduling delivered the largest cannabis-industry tax benefit in forty years, but only to half the industry. For medical-licensed operators that file for DEA registration, set up clean activity segregation, and pick a defensible allocation methodology, FY2026 is a fundamentally different tax year. For operators on the recreational side, nothing has changed — yet — and the entire industry is now waiting on the June 29 hearing to find out whether the same relief flows through to adult-use.
The work between now and the FY2026 return is real: registration, structuring, methodology, protective claims, conformity analysis, position papers. The cost of getting it wrong is large enough that "wait for guidance" is not always the conservative answer. The right answer, for most operators, is to act on the position the Treasury press release signaled while preserving the option to follow formal guidance once it issues.
For weekly updates on Treasury and IRS guidance as it develops, the team at cannabisregulations.ai is tracking the dockets.
